JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Top Cited Papers
- 6 November 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 16 (12), 843-862
- https://doi.org/10.1038/nrd.2017.201
Abstract
The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their associated signalling pathways. Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-molecule inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. Building on the clinical success of first-generation jakinibs, second-generation compounds that claim to be more selective are currently undergoing development and proceeding to clinical trials. However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs. This Review discusses the biology of jakinibs from a translational perspective, focusing on recent insights from clinical trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.Keywords
This publication has 181 references indexed in Scilit:
- Cytokines and Chemokines in Irritant Contact DermatitisMediators of Inflammation, 2013
- Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysisBMC Musculoskeletal Disorders, 2013
- Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic studyArthritis & Rheumatism, 2013
- Origin and Function of Circulating Plasmablasts during Acute Viral InfectionsFrontiers in Immunology, 2012
- Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trialAnnals Of The Rheumatic Diseases, 2011
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)The Journal of Immunology, 2011
- Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health studyArthritis Care & Research, 2009
- Revisiting Crohn's disease as a primary immunodeficiency of macrophagesThe Journal of Experimental Medicine, 2009
- Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritisArthritis Research & Therapy, 2008
- Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosisBlood, 2007